BioCryst Pharmaceuticals, Inc.
BCRX
$9.81
$0.657.10%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 155.06% | -2.42% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 155.06% | -2.42% | |||
| Cost of Revenue | -1.44% | 1.31% | |||
| Gross Profit | 220.09% | -3.90% | |||
| SG&A Expenses | 12.92% | -5.00% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 7.74% | -2.82% | |||
| Operating Income | 801.28% | -0.65% | |||
| Income Before Tax | 1,944.66% | 87.02% | |||
| Income Tax Expenses | 382.44% | -154.89% | |||
| Earnings from Continuing Operations | 1,805.92% | 153.67% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 1,805.92% | 153.67% | |||
| EBIT | 801.28% | -0.65% | |||
| EBITDA | 792.51% | -0.63% | |||
| EPS Basic | 1,797.88% | 152.67% | |||
| Normalized Basic EPS | 1,674.43% | 38.99% | |||
| EPS Diluted | 1,777.67% | 200.00% | |||
| Normalized Diluted EPS | 1,684.16% | 39.60% | |||
| Average Basic Shares Outstanding | 0.38% | 0.31% | |||
| Average Diluted Shares Outstanding | -0.28% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||